Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Syngene COO Dr Mahesh Bhalgat • Source: Syngene

The Indian contract research, development and manufacturing services firm Syngene International Ltd.  says it has what it takes to rein in the cost element to make therapeutics based on the new star modality, messenger RNA (mRNA), “more dominant” across markets.

Syngene’s chief operating officer, Dr Mahesh Bhalgat, said that while the company’s facilities for biologics are also set up to...

More from Business

More from Scrip